Image: PetCure Oncology

Clinical Trials and Research: How PetCure Oncology is Advancing Cancer Care for Pets

PetCure Oncology is on a mission to revolutionize pet cancer care with stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that has been proven effective in humans. To date, we’ve seen SRS/SRT treat many different types of pet cancers in more than 2,000 patients—and our specialists are determined to understand the safety and benefits of SRS/SRT on all tumors.


Whether you’re a pet parent or veterinarian, you may be able to take part in a clinical trial we’re currently conducting. Please see below for more information.

Fiducial trial

PetCure Oncology™ is currently recruiting patients for a clinical trial evaluating the effectiveness of stereotactic radiosurgery (SRS) for the treatment of post-surgical, grade 2 soft tissue sarcoma in dogs using a liquid fiducial marker.

Historically, stereotactic radiation (SRS/SRT) has not been an available treatment option for pet patients who have undergone surgery to remove a malignant tumor. This is due to the lack of an appropriate treatment target, among other factors.

A liquid fiducial marker can be injected along a surgical incision or painted into a resection cavity for later imaging. This allows for the creation of an artificial target that can then be treated with SRS in a single fraction, rather than the 19-21 fractions typically recommended for the treatment of an incompletely resected soft tissue sarcoma. Prior to the launch of this study, PetCure Oncology conducted a pilot study of 20 canine patients whose treatment plans were created using the PetXMark liquid fiducial marker. The pilot study did not result in any acute toxicity, local failures, or geographic misses.

If your dog has soft tissue sarcoma that has residual cancer following surgery, or if you are a veterinarian with a canine patient meeting this criteria, they may be eligible for single-fraction SRS treatment through this clinical trial.


Lung tumor trial

As part of our ongoing commitment to clinical research, PetCure Oncology is launching a clinical trial to evaluate stereotactic radiosurgery (SRS) in the treatment of primary lung tumors in dogs.

Prior to the emergence of SRS, surgery was the primary treatment option for dogs diagnosed with lung tumors. But SRS has changed the way we approach cancer care for pets, offering noninvasive therapy with unprecedented precision that, in many cases, enables the treatment of tumors previously considered “untreatable.” If your pet has been diagnosed with a lung tumor, there may be hope. Studies have shown SRS to be successful in the treatment of lung tumors in humans. This study is intended to prove the hypothesis that dogs can also be safely and effectively treated for lung tumors with SRS.

If your dog has been diagnosed with a primary lung tumor, or if you are a veterinarian with a canine patient that has been diagnosed with one, they may be eligible for subsidized SRS treatment through this clinical trial.